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Abstract 26 
Despite aggressive chemotherapy, approximately one third of children with acute myeloid leukemia (AML) relapse. More effective 27 
treatments are urgently needed. Survivin is an inhibitor-of-apoptosis protein with key roles in regulating cell division, proliferation and 28 
apoptosis. Furthermore, high expression of survivin has been associated with poor clinical outcome in AML. The survivin suppressant 29 
YM155 (sepantronium bromide) has pre-clinical activity against a range of solid cancers and leukemias, although data in AML is limited. 30 
Therefore, we undertook a comprehensive pre-clinical evaluation of YM155 in paediatric AML. YM155 potently inhibited cell viability in a 31 
diverse panel of AML cell lines. All paediatric cell lines were particularly sensitive, with a median IC50 of 0.038 µM. Cell-cycle analyses 32 
demonstrated concentration-dependent increases in a sub-G1 population with YM155 treatment, suggestive of apoptosis that was 33 
subsequently confirmed by an increase in annexin-V positivity. YM155-mediated apoptosis was confirmed across a panel of 7 diagnostic 34 
bone marrow samples from children with AML. Consistent with the proposed mechanism of action, YM155 treatment was associated with 35 
down-regulation of survivin mRNA and protein expression and induction of DNA damage. 36 
These data suggest that YM155-mediated inhibition of survivin is a potentially beneficial therapeutic strategy for AML, particularly 37 
pediatric disease, and warrants further evaluation. 38 
 39 
Introduction 40 
Acute myeloid leukemia (AML) is a clonal disorder of haematopoietic stem cells. It is clinically and genetically heterogeneous, typified by 41 
the accumulation of somatic mutations or aberrations altering the normal cellular functions of proliferation, differentiation and self-42 
renewal [1]. Resistance to conventional chemotherapy remains a major challenge in AML patients with up to 30% of adults and 17% of 43 
children failing to achieve complete remission (CR) [1, 2]. Furthermore, the prognosis for AML patients with refractory disease is 44 
exceptionally poor, where only one third of patients achieve remission with second-line chemotherapy [3]. It is clear that novel 45 
therapeutic strategies are needed, particularly for those patients with primary refractory disease [2, 4].  46 
Survivin is a member of the inhibitor of apoptosis protein (IAP) family and regulates mitosis and apoptosis [5]. Furthermore, Survivin 47 
participates in a chromosomal passenger protein complex with Borealin and Inner Centromere Protein (INCENP) that is essential for 48 
chromosome condensation, spindle assembly and microtubule-kinetochore interactions during chromosome segregation and cytokinesis 49 
[6].  Survivin protein is encoded by the BIRC5 gene and in many normal adult tissues the Survivin transcript is expressed at low or 50 
undetectable levels [7]. In contrast, the BIRC5 gene is one of the most frequently amplified transcripts in cancer [7]. There are several 51 
mechanisms of Survivin upregulation in cancer including amplification of the BIRC5 locus [8], hypomethylation of the BIRC5 promoter [9], 52 
and enhanced promoter activity [5]. Importantly, the upregulation of Survivin in cancer occurs independently of the cell-cycle [5]. This 53 
suggests that the anti-apoptotic function of Survivin may be enhanced in cancer cells compared to normal cells rather than modulation of 54 
the mitotic regulatory function [5]. Hyperactivation of kinase signalling cascades, for example the PI3K, MAPK or STAT3 pathways, in 55 
addition to particular tumour microenvironments such as hypoxia and angiogenesis, induce an upregulation of Survivin expression in many 56 
malignant diseases including neuroblastoma, breast, lung, pancreatic, colon [5] and haematological malignancies [10]. Importantly, there 57 
is a strong correlation between Survivin expression and adverse prognosis, whereby a decreased overall survival rate, increased relapse 58 
rate and enhanced metastatic rate have been observed in several malignant diseases in patients with increased Survivin expression [5, 8, 59 
11-14]. A specific role for Survivin in the promotion and maintenance of leukaemogenesis was recently identified in an in vivo transgenic 60 
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mouse model whereby Survivin overexpressing mice developed haematological malignancies at a faster rate with shorter latency than 61 
control mice [15]. Furthermore, Survivin is highly expressed in CD34+/38- AML [10] and CML progenitors [16, 17] compared to normal 62 
CD34+ and peripheral blood mononuclear cells suggesting that targeting Survivin may be a novel therapeutic strategy in eliminating 63 
putative leukemic stem cells.  64 
Targeted therapies to inhibit Survivin expression have been utilised in an experimental setting including antisense oligonucleotides or 65 
siRNA, vaccination strategies and small molecule inhibitors with promising results to date. All three methodologies have reached clinical 66 
trials including the utilisation of the small molecule inhibitor YM155 (Sepantronium Bromide) for the treatment of solid tumours and 67 
lymphoma [18-32]. Despite the growing body of literature defining the role of Survivin in leukaemogenesis, there is a paucity of pre-clinical 68 
data for YM155 in AML, particularly paediatric disease. Therefore, we undertook a comprehensive preclinical evaluation of YM155 in AML 69 
and show for the first time that YM155 has potent in vitro efficacy in AML, inducing apoptosis at low nanomolar concentrations.  70 
Apoptosis correlated to a reduction in Survivin protein but not gene expression. The induction of cell death was also associated with a 71 
concentration-dependent increase in γ-H2AX phosphorylation, indicative of activation of the DNA damage response. We propose that 72 
YM155 is an effective small molecule that warrants further investigation in AML and may be of particular benefit in paediatrics. 73 
Materials and Methods 74 
Cell culture and reagents 75 
All human AML cell lines were purchased directly from recognised repositories; Kasumi-1, MV4-11, CMK, AML-193, M-07e, HL-60, ML-2, 76 
OCI-AML3, ME-1 and HEL from DSMZ (Braunschweig, Germany) and THP-1 from ATCC (Manassas, USA). The DSMZ and ATCC authenticate 77 
all human cell lines by DNA-typing and confirm species of origin by PCR-analysis. Working stocks for the experiments described in this 78 
study were prepared immediately after the initial thawing of stock cells from DSMZ or ATCC. THP-1, Kasumi-1, MV-411, CMK, HL-60, ML-2, 79 
ME-1 and HEL cells were maintained in RPMI 1640 (Life Technologies, Victoria, Australia); AML-193 and M-07e in IMDM (Life 80 
Technologies) supplemented with 2ng/mL and 10ng/mL of huGMCSF (Peprotech, NJ, USA), respectively and OCI-AML3 in MEMα (Life 81 
Technologies). All cell lines were supplemented with 10% foetal calf serum except M-07e cells that are supplemented with 20% FCS (FCS; 82 
Life Technologies). 83 
Human bone marrow samples from 8 patients with AML were obtained from the Queensland Children’s Tumour Bank. Studies were 84 
approved by Institutional Human Research Ethics Committees and consent given by all patients. Mononuclear cells were isolated by Ficoll-85 
Hypaque density-gradient centrifugation, washed, and resuspended at 5x105 cells/mL in culture media (IMDM; Life Technologies) 86 
supplemented with 0.5% FCS and 1% penicillin/streptomycin. The mean percentage of bone marrow blasts in the primary samples was 87 
80% (± 4.9%, range 64-93%). 88 
Compounds  89 
YM155 (Sepantronium Bromide), cytarabine (cytosine arabinoside) and daunorubicin hydrochloride (daunorubicin) were obtained from 90 
Selleck chemicals (Houston, USA). All compounds were dissolved in DMSO and stored at -20oC.  91 
Cell proliferation, cell cycle and apoptosis assays 92 
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Human AML cell lines (2 x 104 cells/well) were seeded in a 96-well plate with appropriate factors and the indicated concentrations of 93 
compound for 72 hours. Assays were plated in quadruplicate and repeated at least three times. Proliferation was assessed using a 94 
resazurin reduction assay (CellTiter-Blue™, Promega, WI, USA). The concentration of compound that reduced cell viability by 50% (IC50) 95 
was determined using non-linear regression with variable slope after normalising fluorescence to untreated cellular controls. For 96 
combination assays, cells were treated at fixed a concentration of YM155 (0.25 x IC50) with or without Cytarabine or daunorubicin (0.01, 97 
0.1, or 1μM) for 72h. For cell cycle analysis, cells (2 ×105 cells/mL) were seeded in 24-well plates with appropriate factors and the indicated 98 
compound concentrations for 24, 48 or 72h. Assayed cells were fixed in 1 mL 70% ethanol at 4°C. Cells were washed in PBS then incubated 99 
with 40 μg/mL propidium iodide (PI; Sigma Aldrich, MO, USA) and 250 μg/mL RNase (Sigma Aldrich) for 30 minutes at 37°C. Samples were 100 
analyzed on an LSRII FortessaTM flow cytometer (BD Biosciences, NJ, USA), and histograms were fitted for cell cycle ratios using BD 101 
FACSDiva (BD Biosciences). For assessment of H2AXSer319 phosphorylation (γ-H2AX), control cells were exposed to 30 minutes of UV 102 
exposure, where plates were placed within 5cm of a UV light with the plate lid off. 103 
Apoptosis was measured using the annexin-V FITC apoptosis detection kit according to manufacturer’s instructions (BD Biosciences). AML 104 
cell lines were seeded at 2 x 105 cells/mL and primary AML mononuclear cells were seeded at 5 x 105 cells/mL and treated with indicated 105 
concentrations of compound for 72 or 24h respectively. Samples were stained for annexin-V FITC (BioLegend, CA, USA) and PI and 106 
analysed on an LSRII FortessaTM flow cytometer. Data were acquired using the BD FACSDiva software and analysed with FlowJo software.  107 
Immunoblotting 108 
Cells were washed in ice-cold PBS and lysed in a buffer solution (120mM NaCl, 50mM Tris-HCl pH7.4, 1% Triton X-100, 10mM NaF, 10mM 109 
EDTA and supplemented with 0.1% protease inhibitor (Sigma Aldrich)). Total protein (10µg) was separated by SDS-PAGE and transferred 110 
onto nitrocellulose membranes (GE Healthcare, Buckinghamshire, England). Antibodies used for immunoblotting were anti-Survivin and 111 
anti-GAPDH (Cell Signalling Technology, Inc., MA, USA). Membranes were incubated with IRDye® 680LT or IRDye 800CW conjugated 112 
secondary antibodies and protein-antibody complexes visualised by an infrared imaging system. Images were captured with the Odyssey 113 
(LI-COR Biosciences, NE, USA) detection system. 114 
Flow cytometric analysis 115 
Survivin expression was assessed by flow cytometric analysis (FACS) to validate immunoblot results. Briefly, a minimum of 1x105 cells were 116 
fixed in 3.7% formaldehyde/PBS for 10 minutes at room temperature, permeabilized in ice-cold methanol then incubated at -20°C 117 
overnight. Cells were blocked in 5% BSA/PBS for 10 minutes, incubated with either 1:1,000 anti-Survivin or matched IgG isotype control 118 
antibody for 1 hour, then with 1:1,000 Alexa-Flour-680 conjugated anti-Rabbit secondary antibody (Life Technologies Inc.) for 1 hour. 119 
Phosphorylated H2AXSer319 (γ-H2AX) and total H2AX were assessed by FACS. Following treatment, cells were fixed in 1.5% 120 
formaldehyde/PBS for 10 minutes at room temperature, permeabilized in ice-cold methanol and incubated at -20°C overnight. Cells were 121 
washed in 0.5% BSA/PBS/0.02% sodium azide and incubated with either 1:100 anti- γ-H2AX, H2AX (Cell Signalling Technology, Inc.) or 122 
matched IgG isotype control antibody for 1 hour. Samples were then stained with 1:1000 Alexa-Flour-488 conjugated anti-Rabbit 123 
secondary antibody (Life Technologies Inc.) for 1 hour. Samples were analysed on an LSRII FortessaTM flow cytometer. Data were acquired 124 
using the BD FACSDiva software and analysed with FlowJo software. 125 
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Real-time quantitative PCR 126 
Total RNA was extracted from AML cell line pellets containing 1 × 106 cells using the RNeasy mini kit and QIAShredder (Qiagen, Hilden, 127 
Germany) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesised from 500 ng of RNA. For 128 
quantitative, real-time PCR (qRT-PCR) analysis, expression of Survivin (BIRC5) was analysed using a commercially available TAQMAN assay 129 
(Hs03063352_s1) and the ViiATM 7 Real-Time PCR Sequence Detector System (Applied Biosystems, CA, USA). The comparative Ct method 130 
(ΔΔCt) for relative quantification of gene expression was used for analysis with RPS18 gene expression used as an internal control.  131 
Combination treatments 132 
MV4-11 and Kasumi-1 cells (2x105cells/mL) were seeded in 96 well plates and treated with YM155 in combination with either cytarabine 133 
or daunorubicin. Variable concentrations of each compound were used, relative to their single-agent IC50 against each cell line. Assays 134 
were plated in quadruplicate and repeated at least three times. Proliferation was assessed using a resazurin reduction assay. The 135 
percentage of inhibition of proliferation was normalised to DMSO-treated controls. 136 
Statistical analysis 137 
Statistical significance of differences between samples was assessed using a Student's t-test. IC50 values were calculated using non-linear 138 
fit of transformed data normalized to the DMSO-treated control samples. Values shown are the mean ± SEM. All analyses were performed 139 
using GraphPad Prism 6 software (GraphPad Software Inc, CA, USA).  140 
 141 
Results 142 
YM155 inhibits in vitro proliferation of AML cell lines  143 
To determine the in vitro efficacy of YM155 in AML, we utilised a panel of 5 adult and 6 paediatric AML cell lines, representative of the 144 
common cytogenetic and molecular subtypes observed in AML patients (Table 1), and examined the effects of treatment on cell 145 
proliferation. The IC50 values for YM155 against all AML cell lines were in the low nanomolar range (Table 1). When compared to the 146 
conventional chemotherapeutic cytarabine, YM155 showed significantly greater efficacy in 4/6 paediatric AML cell lines and 2/5 adult 147 
lines. Interestingly, YM155 was significantly more potent than cytarabine in all three MLL-rearranged AML cell lines (MV4-11, THP-1 and 148 
ML-2) including the MV4-11 cell line that co-expresses a FLT3 internal tandem duplication (FLT3-ITD) mutation.  149 
YM155 induces apoptotic cell death 150 
Previous studies have suggested that survivin’s tumorigenic properties are a result of an increase in its anti-apoptotic activity, rather than 151 
its role in the cell cycle given that in cancer cells Survivin expression remains consistent throughout the cycle [33]. In order to investigate 152 
whether YM155 has an effect on the cell cycle of paediatric AML cell lines, we performed cell cycle analyses following both time (24, 48 or 153 
72h) and concentration (0-1μM) sensitive treatment. YM155 treatment resulted in a significant increase in the sub-G1 population of 4/6 154 
paediatric AML cell lines (THP-1, AML-193, Kasumi-1 and MV4-11) compared to DMSO treated controls, suggesting induction of cell death 155 
(Figure 1). Sub-G1 accumulation was observed in both a time- (Figure 1b) and concentration-dependent manner (Figure 1c). In order to 156 
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establish the mechanism of cell death observed in cell cycle analysis, we utilised an annexin-V assay. In all cell lines, 72h YM155 treatment 157 
induced a significant concentration-dependent increase in annexin-V+ cells at both 0.1μM and 1μM (Figure 2b). Taken together, these 158 
data indicate that YM155 induces cell death through an apoptotic mechanism. Importantly, YM155 treatment induced apoptosis to a 159 
similar level as the conventional cytotoxic Daunorubicin (Figure 2b).  160 
YM155 down-regulates Survivin expression in paediatric AML cell lines 161 
To determine whether the functional effects of YM155 observed in AML cell lines induced downregulation of Survivin we firstly examined 162 
Survivin protein expression following treatment (0-1μM; 72h). Immunoblot and FACS analyses revealed that YM155 induced a 163 
concentration-dependant reduction in Survivin expression in all 6 paediatric AML cell lines (Figure 3a-c). At 1μM YM155 all cell lines 164 
displayed a reduction in Survivin expression, however a decrease in GAPDH levels was also observed at this high concentration in THP-1, 165 
CMK and AML-193. This is most likely due to the extensive level of cell death and breakdown that occurs after 72h of YM155 treatment. 166 
Previous reports suggest that YM155 blocks Survivin transcription via inhibition of the BIRC5 gene promoter [34]. In order to establish 167 
whether the reduction in Survivin protein expression was due to direct inhibition of gene transcription, we performed qRT-PCR for BIRC5 168 
in the paediatric AML cell lines. BIRC5 gene expression was significantly decreased with 0.1 and 1μM YM155 treatment relative to the 169 
control gene RPS18 across the panel of paediatric AML cell lines (Figure 3d). This finding supports the mechanism of action of YM155 as an 170 
inhibitor of BIRC5 gene promoter activation.  171 
YM155 induces a DNA damage response 172 
Recent studies have demonstrated that YM155 induces a DNA damage response in a panel of solid tumour cell lines [35] but not chronic 173 
lymphocytic leukemia (CLL) cells [36]. Therefore, we assessed the panel of paediatric AML cell lines for induction of γ-H2AX. Interestingly, 174 
only MV4-11 and M07e cells exhibited a significant concentration-dependant increase in γ-H2AX with YM155 treatment compared to 175 
DMSO controls (Figure 4). MV4-11 were the most sensitive to DNA damage induction with a mean 6.7 (±0.2)-fold induction of γ-H2AX 176 
relative to H2AX expression and normalised to DMSO controls (p=0.0002) following 1μM YM155 treatment (Figure 4E). The conventional 177 
cytotoxic compounds cytarabine (Ara-C; 1μM) and daunorubicin (1μM), and 30 minutes of direct UV exposure also induced γ-H2AX 178 
expression in these cell lines (Figure 4), however not to the same extent as YM155. This suggests that YM155 may not only mediate AML 179 
cell death by affecting Survivin expression, but also by inducing DNA damage in cells expressing certain molecular backgrounds. Kasumi-1 180 
cells also exhibited and increase in γ-H2AX relative to H2AX expression, however did not reach significance. Given that CMK, AML193 and 181 
THP-1 cells did not exhibit DNA damage response activation with YM155, cytotoxic or UV treatment suggests they are inherently resistant 182 
to γ-H2AX mediated DNA damage from multiple sources. 183 
YM155 increases the cytotoxicity of conventional chemotherapy in AML cells 184 
Since conventional treatment of AML is based on intensive use of cytarabine and anthracyclines, we set out to establish whether YM155 in 185 
combination with these drugs would increase their anti-leukemic effects. MV4-11 and Kasumi-1 cells were co-cultured with cytarabine or 186 
daunorubicin in the presence or absence of YM155 for 72h and proliferation measured. Combination treatment was more effective at 187 
inhibiting the proliferation of both MV4-11 and Kasumi-1 cells compared to either compound alone (Figure 5).  188 
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YM155 induces cell death of AML patient blasts  189 
To determine if primary human AML cells are sensitive to YM155, paediatric AML blasts from 8 patients with diverse cytogenetic and 190 
molecular characteristics (including 1 with acute promyelocytic leukemia, selected due to the presence of a dual FLT3-ITD-D835 mutation; 191 
Table 2) were treated with increasing concentrations of YM155 (0-1μM) for 24h. Cell death was assessed by annexin-V/PI staining. YM155 192 
treatment induced a concentration-dependent increase in annexin-V+ cells (Figure 6A) and concomitant reduction in the percentage of 193 
live viable cells (annexin-V- / PI-; Figure 6B). Of note, four of the five most sensitive AML patient samples had FLT3 mutations (Table 2). 194 
Internal duplication of the FLT3 tyrosine kinase gene (FLT3-ITD) is a frequent event in AML and is associated with higher relapse rates and 195 
reduced survival [37]. When grouped according to FLT3 status, there appeared to be a trend toward greater sensitivity of those patients 196 
expressing FLT3-ITD compared to FLT3-WT patient blasts at all concentrations of YM155 however this did not reach significance (Figure 6C 197 
and D).  198 
Discussion 199 
This study has shown that the small molecule Survivin inhibitor YM155 is efficacious for the inhibition of paediatric AML cell growth in 200 
vitro. Treatment of AML cell lines with nanomolar concentrations of YM155 lead to inhibition of proliferation and accumulation of a sub-201 
G1 population due to an induction of apoptotic cell death, in both a time and concentration dependent manner. Importantly, the efficacy 202 
of YM155 was not limited to established AML cell lines, with primary samples from paediatric patients with AML also displaying 203 
therapeutic sensitivity. Inhibition of proliferation and induction of apoptosis was associated with downregulation of Survivin protein and 204 
gene expression. Induction of the DNA damage response as measured by γ-H2AX expression was also evident in a subset of cell lines. 205 
Survivin is a small inhibitor-of-apoptosis protein involved in regulating apoptosis, the cell cycle and the cellular stress response. The 206 
overexpression and nodal characteristics of Survivin including resistance to apoptosis, metastasis, circumvention of cell cycle checkpoints 207 
and resistance to chemotherapy make it an attractive therapeutic target for a range of human cancers [5]. Several strategies have been 208 
utilised to suppress Survivin expression and concomitantly target its cancer promoting networks including antisense oligonucleotides [5, 209 
38-40] and the small molecule YM155 [5, 34]. YM155 was reported to bind to the Survivin promoter, modulating gene expression in 210 
human prostate tumour models [34]. This supports observations in our in vitro paediatric AML model whereby the mRNA expression was 211 
reduced with YM155 treatment (0.1, 1μM; 72h), and was associated with a concomitant reduction in Survivin protein expression; a finding 212 
validated by both immunoblotting and flow cytometric analyses. Taken together, these data suggest that YM155 regulates Survivin 213 
expression at the transcriptional level in AML cells.  214 
Although YM155 was originally considered a small molecule inhibitor of Survivin promoter activity, recent studies have revealed that 215 
YM155 treatment results in other functional effects including DNA damage [35]. Glaros et. al. reported that YM155 had broad potency 216 
against the NCI-60 cell line panel with IC50 values in the nanomolar range, attributable to an induction of γ-H2AX and pKAP1 expression. 217 
Importantly, the activation of this alternative cellular pathway occurred at concentrations lower than those required to inhibit Survivin 218 
protein expression in PC3 prostate cancer cells [35]. This suggests that DNA damage preceded Survivin inhibition, at least in PC3 cells, and 219 
contributed to cell death earlier and more potently than Survivin downregulation. Further evidence for the function of YM155 as a DNA 220 
damaging agent arose when the authors compared YM155 to three well characterised DNA damaging agents (chromomyocin A3, 221 
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bisantrene HCl and actinomyocin D) and found significant concordance between the compounds (R=0.864, 0.705 and 0.689 respectively) 222 
[35]. Similarly, an earlier study identified downregulation of the Bcl-2 family member, Mcl-1, as a mediator of YM155-induced apoptosis in 223 
a wide range of established cancer cell lines [41]. Mcl-1 is a pro-survival protein that protects cells from stimuli-mediated cell death 224 
resulting from activation of the intrinsic apoptotic pathway. YM155 treatment was shown to downregulate Mcl-1 expression in a time- and 225 
concentration-dependent manner [41]. Importantly, downregulation of Mcl-1 was independent of, and preceded the downregulation of 226 
Survivin suggesting that Survivin downregulation is not an isolated mechanism of action of YM155 and may not be the initiating apoptotic 227 
event. These studies support our observations of an induction of γ-H2AX expression in parallel with a downregulation of Survivin, 228 
suggestive of a dual function of YM155. However, this effect was only observed in 2 of 6 paediatric AML cell lines (MV4-11 and M07e). 229 
Similarly, the cytotoxic chemotherapeutic drugs cytarabine and daunorubicin both induced a DNA damage response in MV4-11 and M07e 230 
cells in vitro, further supporting the notion that YM155 may act primarily as a cytotoxic DNA-damaging agent, rather than a specific 231 
Survivin inhibitor. The lack of DNA damage response activation following all treatments including UV exposure in the CMK, AML-193, and 232 
THP-1 cells suggests that these cells may be particularly resistant to DNA damaging stimuli, and alternative mechanisms of action of 233 
YM155 such as its BIRC5 promotor binding activity likely account for the nanomolar sensitivity of these cell lines. The accumulation of a 234 
sub-G1 population in cells in cell cycle assays, induction of y-H2AX phosphorylation in selected cell lines and induction of annexin V 235 
positivity suggests that YM155 sensitivity may induce cell death through a number of mechanisms including mitotic catastrophe, DNA 236 
damage and apoptosis. 237 
Patient samples positive for FLT3-ITD were particularly sensitive to YM155 in vitro, consistent with the low-nanomolar IC50 demonstrated 238 
for the FLT3-ITD+ cell line, MV4-11. Although there was no statistical significance between FLT3-ITD+ and FLT3-WT+ samples, the trend 239 
raises the possibility of a differential effect in FLT3-ITD+ AML; a larger cohort of FLT3-ITD+ and FLT3-WT samples is needed to confirm this. 240 
Previous studies support these findings; it has been reported that Survivin plays a critical role in proliferation of AML cells harbouring FLT3-241 
ITD and resistance to FLT3 kinase inhibition. Survivin was over-expressed in pre-clinical models of FLT3-inhibitor resistance and was 242 
identified as a downstream transcription target of the FLT3-STAT pathway [42]. Survivin expression and STAT activation were both 243 
increased when MV4-11 cells were cultured long-term with the FLT3 inhibitor ABT-869. Sensitivity to ABT-869 in these resistant MV4-11 244 
cells was restored by silencing Survivin with shRNA. Furthermore, Survivin over-expression in transfected parent MV4-11 cells, conferred 245 
resistance to FLT3 inhibition [42]. Survivin expression has also been shown to be higher in FLT3-ITD transfected Ba/F3 cells and FLT3-ITD+ 246 
primary samples compared to FLT3-WT samples [43]. Furthermore, studies using Survivin knock-out mice suggest that it regulates FLT3-247 
ITD driven proliferation [43]. Taken together, this evidence suggests that YM155 may be of particular benefit to patients with FLT3-ITD+ 248 
AML. Importantly, 2 primary patient samples harbouring FLT3-ITD and a secondary tyrosine kinase domain (TKD) mutation at D835 were 249 
sensitive to YM155. Dual FLT3-ITD-TKD mutations have recently been identified as a mechanism of FLT3 inhibitor resistance [4, 37, 44-46], 250 
suggesting that YM155 may offer a therapeutic option for this subset of patients and further investigation is warranted. 251 
Early phase clinical trials of YM155 have thus far shown that YM155 is generally well tolerated and clinical responses have been seen in a 252 
range of tumour types [47]. Given the very short half-life of YM155, most trials have thus far assessed continuous 7 day infusions. 253 
Liposomal formulations of YM155 are being developed, which may facilitate weekly bolus dosing [48]. Although the exact mechanism of 254 
action of YM155 as a specific Survivin suppressant is debated, it is acknowledged that YM155 may remain a valuable anti-cancer agent 255 
[47]. Importantly, our data shows that in vitro combination of YM155 with daunorubicin and cytarabine increases the effectiveness of 256 
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these clinically relevant chemotherapeutic agents against AML cell lines. These data are of importance to clinical trial design in AML, since 257 
cytarabine and anthracyclines form the backbone of upfront therapy and low dose cytarabine is commonly used in combination for early-258 
phase trials of novel therapeutics.  259 
The preclinical data presented here demonstrate for the first time that AML may be a malignancy with particular sensitivity to YM155. 260 
Whether YM155 functions primarily through the inhibition of Survivin gene expression or other mechanisms, such as DNA damage, 261 
remains unclear. However, given the urgent need for novel therapeutic approaches in AML, the potent in vitro efficacy demonstrated here 262 
and the relative safety profile from recent trials in other malignancies, clinical evaluation of YM155 in AML is warranted. It will be 263 
important to ensure that the design of such clinical trials allows for expansion cohorts of subtypes such as FLT3-ITD, if initial clinical 264 
sensitivity reflects the preclinical data reported here. Furthermore, the paucity of novel agents available for children with AML demands 265 
that adult phase I trials are promptly followed by paediatric trials once the adult safety profile in acute leukemia is established. 266 
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Tables 386 
Table 1.  YM155 inhibits in vitro proliferation of AML cell lines at nanomolar concentrations 387 
 388 
389 
1IC50; is defined as the concentration of drug that reduces cell viability by 50%, calculated by non-linear regression. The IC50 ratio was 390 
calculated by dividing the IC50 of YM155 by the IC50 of Daunorubicin or Cytarabine. P-value determined by students t-test. 391 
Abbrev: Daun; daunorubicin, Cyt; cytarabine, FAB; French-American-British classification,  SEM; standard error of the mean. 392 
 393 
Table 2. Patient characteristics 394 
395 
 δPatients ranked according to sensitivity (1 highest sensitivity, 9 least sensitivity) to YM155 (1μM;24h) measured by percent of Annexin-V+ 396 
cells by FACS analysis. *This sample was acute ambiguous lineage leukemia, with populations consistent with B-cell and myeloid leukemia. 397 
The t(9;22) resulted in an e1a2 BCR/ABL1 transcript. The t(1;11) was unbalanced with no rearrangement of the MLL gene.  398 
Abbrev: ID; identification, Dx; diagnosis, F; female, M; male, AML; acute myeloid leukemia, APL; acute promyelocytic leukemia.  399 
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Figure Legends 400 
Figure 1. YM155 induces Sub-G1 accumulation of AML cells. A) Representative histogram of accumulation of a sub-G1 population of THP1 401 
cells treated with DMSO or 1μM YM155 for 72h. B) AML cell lines were grown in the presence of YM155 (1μM) for indicated times. C) AML 402 
cell lines were grown in the indicated concentrations of YM155 for 72h. Propidium iodide was used to assess DNA content by flow 403 
cytometric analysis. Columns; mean percent of cells in Sub-G1, bars; SEM. *p<0.05, **p<0.01, Students t-test compared to DMSO controls.  404 
Figure 2. YM155 induces apoptosis in AML cells. A) Representative dot plot of apoptosis induction showing THP1 cells treated with DMSO, 405 
1μM Daunorubicin or 1μM YM155 for 72h. B) AML cell lines were grown in the presence of YM155 (1μM) for indicated times. B) AML cell 406 
lines were treated with indicated concentrations of Daunorubicin or YM155 for 72h. Levels of apoptosis were measured by an annexin-V 407 
apoptosis assay.  Percent apoptosis was defined as all cells expressing Annexin V positivity (addition of quadrant 2 and quadrant 4 of dot 408 
plot). Points, mean of at least 3 independent experiments; bars, SEM. *p<0.05. Students t-test relative to DMSO control. 409 
Figure 3. YM155 induces downregulation of Survivin in AML cells. Survivin expression was assessed qualitatively by A) immunoblot and B) 410 
quantitatively by flow cytometry. GAPDH was used as a loading control. C) Flow cytometry data represents all paediatric cell lines, the bars 411 
denote mean±SEM D) RT-PCR was used to analyse the expression of BIRC5 gene expression in paediatric AML cell lines. ∆CT is BIRC5 412 
normalised to RSP18 relative to DMSO control. Points: mean of 3 independent experiments, bars: SEM. *p<0.05, ***p<0.005 compared to 413 
control. Immunoblots are representative of at least 3 independent experiments. 414 
Figure 4. YM155 induces DNA damage. A) CMK, B) Mo7e, C) AML-193, D) Kasumi-1, E) MV4-11 and F) THP-1 cells were incubated in 415 
increasing concentrations of YM155, Ara-C (1μM) or Daunorubicin (1μM) for 72h. Following 72h treatment, half the DMSO control cells 416 
were subject to 30minutes of direct UV exposure. The level of pH2AXSer319 and total H2AX was determined by immunofluorescence and 417 
FACS analysis. Data was analysed by dividing the percentage of γH2AXSer319 positive cells by the percentage of total H2AX positive cells and 418 
normalising to DMSO controls. Column, mean of 3 independent experiments; Bars, SEM. *p<0.05,**p<0.01, ***p<0.005. Students t-test 419 
relative to DMSO control. 420 
Figure 5. YM155 enhances the anti-proliferative effect of chemotherapy. A) MV411 or B) Kasumi 1 cells were incubated with YM155 (0.25 421 
x IC50) in the presence or absence of i) 0.5 x IC50 or ii) 1 x IC50 of Daunorubicin or iii) 0.5 x IC50 or iv) 1 x IC50 of Cytarabine for 72h. Following 422 
72h treatment, cells were subject to a resazurin reduction assay. Percentages were normalised to DMSO controls. Column, mean of 3 423 
independent experiments; Bars, SEM. *p<0.05, **p<0.01, ***p<0.005. Students t-test. Similar trends were observed with 0.5 x and 1 x IC50  424 
of YM155 in combination with Daunorubicin or Cytarabine (data not shown).  425 
Figure 6. YM155 induces apoptosis of primary paediatric AML blasts. AML mononuclear cells were incubated in increasing concentrations 426 
of YM155 for 24h. The level of apoptosis was determine by an annexin V apoptosis assay and all cells negative for annexin V or PI staining 427 
were deemed live cells whilst cells positive for annexin V were deemed apoptotic. A) Representative dot plot of AML patient mononuclear 428 
cells treated with DMSO, 1μM Daunorubicin or 1μM YM155 showing induction of apoptosis. B) The ratio of annexin V+ cells significantly 429 
increased with increasing YM155 concentration. B) The percentage of live cells significantly decreased with increasing concentrations of 430 
YM155. FLT3-ITD+ blasts are sensitive to C) induction of apoptosis and D) reduced viability compared to FLT3 wild-type (FLT3-WT) patient 431 
blasts. Points, individual patient values; Column, mean (n=4); Bars, SEM. *p<0.05, **p<0.01, ***p<0.005. Students t-test relative to DMSO 432 
control. 433 
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